Gregory Forlenza
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Infusion Systems | 92 | 2026 | 477 | 17.290 |
Why?
| | Diabetes Mellitus, Type 1 | 115 | 2026 | 3890 | 12.400 |
Why?
| | Insulin | 94 | 2026 | 2507 | 9.410 |
Why?
| | Blood Glucose Self-Monitoring | 79 | 2026 | 699 | 9.130 |
Why?
| | Hypoglycemic Agents | 89 | 2026 | 1387 | 9.080 |
Why?
| | Pancreas, Artificial | 31 | 2025 | 97 | 8.840 |
Why?
| | Blood Glucose | 104 | 2026 | 2327 | 8.570 |
Why?
| | Hypoglycemia | 35 | 2026 | 477 | 5.700 |
Why?
| | Hyperglycemia | 15 | 2023 | 375 | 3.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2022 | 675 | 1.990 |
Why?
| | Diabetes Mellitus | 10 | 2025 | 1098 | 1.700 |
Why?
| | Islets of Langerhans Transplantation | 5 | 2024 | 67 | 1.630 |
Why?
| | Monitoring, Ambulatory | 5 | 2018 | 88 | 1.630 |
Why?
| | Child | 66 | 2026 | 22633 | 1.470 |
Why?
| | Adolescent | 67 | 2026 | 22428 | 1.440 |
Why?
| | Pancreatectomy | 5 | 2024 | 285 | 1.370 |
Why?
| | Algorithms | 18 | 2025 | 1837 | 1.370 |
Why?
| | Humans | 147 | 2026 | 144759 | 1.320 |
Why?
| | Insulin-Secreting Cells | 3 | 2023 | 388 | 1.260 |
Why?
| | Pancreatitis, Chronic | 4 | 2024 | 63 | 1.170 |
Why?
| | Biomedical Technology | 2 | 2019 | 49 | 1.110 |
Why?
| | Young Adult | 39 | 2026 | 14105 | 1.090 |
Why?
| | Verapamil | 2 | 2023 | 37 | 0.990 |
Why?
| | Patient Education as Topic | 3 | 2021 | 780 | 0.960 |
Why?
| | Diabetes Mellitus, Type 2 | 8 | 2025 | 2583 | 0.950 |
Why?
| | Adult | 56 | 2026 | 40449 | 0.920 |
Why?
| | Male | 64 | 2026 | 72315 | 0.830 |
Why?
| | Technology | 5 | 2023 | 95 | 0.790 |
Why?
| | Telemedicine | 3 | 2022 | 945 | 0.770 |
Why?
| | Female | 63 | 2026 | 78271 | 0.770 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 165 | 0.740 |
Why?
| | Caregivers | 3 | 2025 | 1049 | 0.700 |
Why?
| | Child, Preschool | 19 | 2025 | 11787 | 0.680 |
Why?
| | Lymphoma | 1 | 2023 | 232 | 0.670 |
Why?
| | Self-Management | 2 | 2026 | 201 | 0.670 |
Why?
| | Glucose | 9 | 2024 | 1047 | 0.650 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 293 | 0.600 |
Why?
| | Patient Dropouts | 1 | 2020 | 65 | 0.600 |
Why?
| | Treatment Outcome | 19 | 2026 | 11679 | 0.590 |
Why?
| | Patient Satisfaction | 3 | 2024 | 704 | 0.570 |
Why?
| | Personal Satisfaction | 1 | 2020 | 222 | 0.560 |
Why?
| | Diabetic Ketoacidosis | 5 | 2024 | 210 | 0.540 |
Why?
| | Eczema | 1 | 2018 | 66 | 0.530 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 186 | 0.530 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.510 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 208 | 0.490 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 98 | 0.490 |
Why?
| | Machine Learning | 2 | 2025 | 585 | 0.450 |
Why?
| | Endocrine Glands | 1 | 2015 | 14 | 0.450 |
Why?
| | Insulin, Regular, Human | 7 | 2023 | 47 | 0.450 |
Why?
| | Quality of Life | 4 | 2024 | 3185 | 0.450 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 290 | 0.440 |
Why?
| | Retrospective Studies | 13 | 2025 | 17066 | 0.440 |
Why?
| | Endocrine System Diseases | 1 | 2015 | 35 | 0.440 |
Why?
| | Insulin Lispro | 3 | 2024 | 42 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Aged | 21 | 2026 | 25913 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | C-Peptide | 3 | 2025 | 189 | 0.430 |
Why?
| | Artificial Intelligence | 1 | 2019 | 365 | 0.420 |
Why?
| | Exercise | 9 | 2025 | 2201 | 0.420 |
Why?
| | Fanconi Anemia | 1 | 2013 | 11 | 0.410 |
Why?
| | United States | 16 | 2026 | 15966 | 0.410 |
Why?
| | Dwarfism | 1 | 2013 | 15 | 0.410 |
Why?
| | Cross-Over Studies | 7 | 2026 | 601 | 0.400 |
Why?
| | Growth Hormone | 1 | 2013 | 92 | 0.400 |
Why?
| | Awareness | 2 | 2026 | 108 | 0.400 |
Why?
| | Skin | 1 | 2018 | 755 | 0.390 |
Why?
| | Middle Aged | 24 | 2026 | 35875 | 0.390 |
Why?
| | Blindness | 1 | 2012 | 52 | 0.370 |
Why?
| | Suicide | 1 | 2020 | 720 | 0.360 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 824 | 0.360 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 549 | 0.350 |
Why?
| | Pandemics | 1 | 2020 | 1694 | 0.340 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 237 | 0.330 |
Why?
| | Biosensing Techniques | 2 | 2025 | 139 | 0.330 |
Why?
| | Calibration | 3 | 2020 | 151 | 0.330 |
Why?
| | Lingual Frenum | 1 | 2010 | 2 | 0.320 |
Why?
| | Tongue Diseases | 1 | 2010 | 9 | 0.320 |
Why?
| | Failure to Thrive | 1 | 2010 | 28 | 0.320 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2168 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1720 | 0.310 |
Why?
| | Epidemics | 1 | 2011 | 98 | 0.310 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 557 | 0.310 |
Why?
| | Medicaid | 3 | 2022 | 461 | 0.300 |
Why?
| | Medicare | 3 | 2025 | 886 | 0.300 |
Why?
| | Models, Biological | 1 | 2016 | 1821 | 0.290 |
Why?
| | Double-Blind Method | 4 | 2023 | 2029 | 0.290 |
Why?
| | Infant | 6 | 2023 | 10034 | 0.280 |
Why?
| | Skiing | 2 | 2019 | 49 | 0.270 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5408 | 0.260 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 2 | 2017 | 29 | 0.260 |
Why?
| | Inventions | 2 | 2018 | 19 | 0.260 |
Why?
| | Prospective Studies | 7 | 2025 | 7990 | 0.250 |
Why?
| | Insurance Coverage | 2 | 2025 | 239 | 0.250 |
Why?
| | Endocrinology | 2 | 2018 | 77 | 0.230 |
Why?
| | Feasibility Studies | 6 | 2026 | 1095 | 0.230 |
Why?
| | Meals | 4 | 2024 | 130 | 0.230 |
Why?
| | Insulin Aspart | 2 | 2022 | 30 | 0.230 |
Why?
| | Outpatients | 2 | 2021 | 442 | 0.230 |
Why?
| | Injections, Subcutaneous | 3 | 2020 | 164 | 0.220 |
Why?
| | Overweight | 2 | 2023 | 609 | 0.220 |
Why?
| | Risk Factors | 5 | 2020 | 10779 | 0.220 |
Why?
| | Postoperative Complications | 2 | 2015 | 2919 | 0.220 |
Why?
| | Body Height | 2 | 2017 | 202 | 0.210 |
Why?
| | Mutation | 1 | 2015 | 4089 | 0.200 |
Why?
| | Eligibility Determination | 1 | 2022 | 68 | 0.190 |
Why?
| | Insulins | 1 | 2023 | 38 | 0.190 |
Why?
| | Equipment Failure | 3 | 2018 | 115 | 0.190 |
Why?
| | Patient Safety | 1 | 2025 | 347 | 0.180 |
Why?
| | Pediatrics | 2 | 2020 | 1114 | 0.170 |
Why?
| | Automobile Driving | 1 | 2023 | 155 | 0.160 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 26 | 0.160 |
Why?
| | Computer Systems | 1 | 2020 | 56 | 0.160 |
Why?
| | Smartphone | 2 | 2019 | 102 | 0.150 |
Why?
| | Europe | 3 | 2025 | 412 | 0.150 |
Why?
| | Sports | 2 | 2019 | 211 | 0.150 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2019 | 72 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2020 | 307 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2024 | 3409 | 0.140 |
Why?
| | Prevalence | 3 | 2023 | 2834 | 0.140 |
Why?
| | Clinical Alarms | 1 | 2017 | 10 | 0.140 |
Why?
| | Software | 2 | 2021 | 690 | 0.130 |
Why?
| | Night Terrors | 1 | 2017 | 1 | 0.130 |
Why?
| | Insulinoma | 1 | 2017 | 28 | 0.130 |
Why?
| | Device Approval | 1 | 2017 | 19 | 0.130 |
Why?
| | Diet, Diabetic | 1 | 2017 | 33 | 0.130 |
Why?
| | Voluntary Health Agencies | 1 | 2016 | 6 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1382 | 0.130 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 39 | 0.120 |
Why?
| | Program Evaluation | 1 | 2021 | 948 | 0.120 |
Why?
| | Pancreaticoduodenectomy | 1 | 2017 | 135 | 0.120 |
Why?
| | Obesity | 3 | 2023 | 3077 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 203 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 284 | 0.120 |
Why?
| | Abdominal Pain | 1 | 2017 | 146 | 0.120 |
Why?
| | Hypophosphatasia | 1 | 2015 | 5 | 0.110 |
Why?
| | Age Factors | 3 | 2018 | 3333 | 0.110 |
Why?
| | Drug Overdose | 1 | 2020 | 370 | 0.110 |
Why?
| | Automation | 2 | 2025 | 102 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 380 | 0.110 |
Why?
| | Alkaline Phosphatase | 1 | 2015 | 145 | 0.110 |
Why?
| | History, 21st Century | 2 | 2025 | 219 | 0.110 |
Why?
| | Autografts | 1 | 2014 | 55 | 0.110 |
Why?
| | Pilot Projects | 2 | 2020 | 1886 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2022 | 1098 | 0.100 |
Why?
| | History, 20th Century | 2 | 2025 | 325 | 0.100 |
Why?
| | Choristoma | 1 | 2013 | 21 | 0.100 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 199 | 0.100 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2013 | 40 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 423 | 0.100 |
Why?
| | Postoperative Period | 1 | 2014 | 354 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 359 | 0.100 |
Why?
| | Pituitary Gland | 1 | 2013 | 148 | 0.100 |
Why?
| | Graft Survival | 1 | 2015 | 526 | 0.100 |
Why?
| | Allografts | 1 | 2013 | 150 | 0.100 |
Why?
| | Bionics | 2 | 2022 | 14 | 0.090 |
Why?
| | Patient Compliance | 1 | 2017 | 588 | 0.090 |
Why?
| | Clinical Protocols | 1 | 2014 | 282 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6048 | 0.090 |
Why?
| | Graft Rejection | 1 | 2015 | 540 | 0.090 |
Why?
| | Genetic Testing | 1 | 2015 | 478 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1289 | 0.090 |
Why?
| | Adolescent Behavior | 1 | 2017 | 501 | 0.090 |
Why?
| | Pituitary Neoplasms | 1 | 2013 | 190 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 652 | 0.090 |
Why?
| | Body Mass Index | 2 | 2017 | 2438 | 0.090 |
Why?
| | Prognosis | 2 | 2020 | 4282 | 0.080 |
Why?
| | Age of Onset | 1 | 2012 | 551 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2947 | 0.080 |
Why?
| | Biomedical Research | 1 | 2016 | 710 | 0.080 |
Why?
| | Critical Illness | 1 | 2016 | 891 | 0.080 |
Why?
| | Activities of Daily Living | 3 | 2017 | 441 | 0.070 |
Why?
| | Global Health | 1 | 2012 | 401 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 919 | 0.070 |
Why?
| | Consensus | 2 | 2022 | 488 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4271 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1173 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2012 | 589 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3604 | 0.070 |
Why?
| | Equipment Design | 2 | 2019 | 530 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 887 | 0.070 |
Why?
| | Hospitalization | 3 | 2024 | 2433 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2019 | 6429 | 0.060 |
Why?
| | Cold Temperature | 2 | 2019 | 209 | 0.060 |
Why?
| | Weight Gain | 1 | 2010 | 556 | 0.060 |
Why?
| | Breast Feeding | 1 | 2010 | 448 | 0.060 |
Why?
| | Disposable Equipment | 1 | 2026 | 24 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2879 | 0.060 |
Why?
| | Time Factors | 3 | 2025 | 7173 | 0.060 |
Why?
| | Seasons | 2 | 2019 | 556 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1560 | 0.050 |
Why?
| | Risk | 2 | 2017 | 911 | 0.050 |
Why?
| | Child Abuse | 1 | 2010 | 551 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1266 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1347 | 0.050 |
Why?
| | Diet | 1 | 2011 | 1273 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 121 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2025 | 433 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2011 | 1241 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 80 | 0.050 |
Why?
| | Pregnancy | 2 | 2025 | 7190 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2026 | 8265 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 177 | 0.040 |
Why?
| | Cohort Studies | 2 | 2025 | 5960 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 80 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2023 | 634 | 0.040 |
Why?
| | Social Conditions | 1 | 2019 | 13 | 0.040 |
Why?
| | Pancreas | 1 | 2022 | 341 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 545 | 0.040 |
Why?
| | Disease Management | 1 | 2023 | 645 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 35 | 0.040 |
Why?
| | Health Personnel | 1 | 2025 | 748 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 198 | 0.030 |
Why?
| | Postprandial Period | 1 | 2018 | 118 | 0.030 |
Why?
| | Virginia | 1 | 2017 | 55 | 0.030 |
Why?
| | Snacks | 1 | 2017 | 23 | 0.030 |
Why?
| | Colorado | 2 | 2017 | 4564 | 0.030 |
Why?
| | Ohio | 1 | 2017 | 145 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 797 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 196 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 106 | 0.030 |
Why?
| | Minnesota | 1 | 2017 | 169 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 119 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 312 | 0.030 |
Why?
| | Hypertrophy | 1 | 2016 | 127 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 126 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 354 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2022 | 727 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 552 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 684 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1356 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2925 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3863 | 0.010 |
Why?
|
|
Forlenza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|